Merus BV (MRUS) - Total Assets
Based on the latest financial reports, Merus BV (MRUS) holds total assets worth $771.99 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Merus BV cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Merus BV - Total Assets Trend (2012–2024)
This chart illustrates how Merus BV's total assets have evolved over time, based on quarterly financial data. See Merus BV book value and equity for net asset value and shareholders' equity analysis.
Merus BV - Asset Composition Analysis
Current Asset Composition (December 2024)
Merus BV's total assets of $771.99 Million consist of 72.5% current assets and 27.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 37.4% |
| Accounts Receivable | $4.71 Million | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.68 Million | 0.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Merus BV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Merus BV market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Merus BV's current assets represent 72.5% of total assets in 2024, a decrease from 85.6% in 2012.
- Cash Position: Cash and equivalents constituted 37.4% of total assets in 2024, down from 73.6% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 11.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Merus BV Competitors by Total Assets
Key competitors of Merus BV based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
Merus BV - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.97 | 8.32 | 4.66 |
| Quick Ratio | 7.97 | 8.32 | 4.50 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $516.65 Million | $586.20 Million | $171.25 Million |
Merus BV - Advanced Valuation Insights
This section examines the relationship between Merus BV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.81 |
| Latest Market Cap to Assets Ratio | 8.69 |
| Asset Growth Rate (YoY) | 72.4% |
| Total Assets | $785.13 Million |
| Market Capitalization | $6.83 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Merus BV's assets at a significant premium (8.69x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Merus BV's assets grew by 72.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Merus BV (2012–2024)
The table below shows the annual total assets of Merus BV from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $785.13 Million | +72.37% |
| 2023-12-31 | $455.49 Million | +20.97% |
| 2022-12-31 | $376.54 Million | -17.53% |
| 2021-12-31 | $456.60 Million | +97.48% |
| 2020-12-31 | $231.22 Million | -12.21% |
| 2019-12-31 | $263.38 Million | +5.37% |
| 2018-12-31 | $249.96 Million | +5.87% |
| 2017-12-31 | $236.11 Million | +210.47% |
| 2016-12-31 | $76.05 Million | +95.97% |
| 2015-12-31 | $38.81 Million | +801.48% |
| 2014-12-31 | $4.30 Million | -74.91% |
| 2013-12-31 | $17.16 Million | +61.53% |
| 2012-12-31 | $10.62 Million | -- |
About Merus BV
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the… Read more